Rifampicin in treating S aureus bacteraemia - Authors' reply by Thwaites, G, Szubert, A, Walker, A

Pubertal development in HIV-infected African children on first-line antiretroviral therapy. by Szubert, A, Musiime, V, Bwakura-Dangarembizi, M, Nahirya-Ntege, P, Kekitiinwa, A, Gibb, D, Nathoo, K, Prendergast, A, Walker, A

Virologic response to first-line efavirenz- or nevirapine-based anti-retroviral therapy in HIV-infected African children by Kekitiinwa, A, Szubert, A, Spyer, M, Katuramu, R, Musiime, V, Mhute, T, Bakeera–Kitaka, S, Senfuma, O, Mujoma, M, Walker, A, Gibb, D

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities. by Dennis, M, Culligan, D, Karamitros, D, Vyas, P, Johnson, P, Russell, N, Cavenagh, J, Szubert, A, Hartley, S, Brown, J, Bowen, D

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children by Kekitiinwa, A, Szubert, A, Spyer, M, Katuramu, R, Musiime, V, Mhute, T, Bakeera-Kitaka, S, Senfuma, O, Walker, A, Gibb, D, ARROW Trial Team

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years. by Musoke, P, Szubert, A, Musiime, V, Nathoo, K, Nahirya-Ntege, P, Mutasa, K, Williams, D, Prendergast, A, Spyer, M, Walker, A, Gibb, D

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy. by Bwakura-Dangarembizi, M, Musiime, V, Szubert, A, Prendergast, A, Gomo, Z, Thomason, M, Musarurwa, C, Mugyenyi, P, Nahirya, P, Kekitiinwa, A, Gibb, D, Walker, A, Nathoo, K

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe by Prendergast, A, Berejena, C, Pimundu, G, Shonhai, A, Bwakura-Dangarembizi, M, Musiime, V, Szubert, A, Cook, A, Spyer, M, Nahirya-Ntege, P, Kekitiinwa, A, Gibb, D, Klein, N, Walker, A

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational anal... by Szubert, A, Prendergast, A, Spyer, M, Musiime, V, Musoke, P, Bwakura-Dangarembizi, M, Nahirya-Ntege, P, Thomason, M, Ndashimye, E, Nankya, I, Senfuma, O, Mudenge, B, Klein, N, Gibb, D, Walker, A

Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy by Prendergast, A, Szubert, A, Berejena, C, Pimundu, G, Pala, P, Shonhai, A, Musiime, V, Bwakura-Dangarembizi, M, Poulsom, H, Hunter, P, Musoke, P, Kihembo, M, Munderi, P, Gibb, D, Spyer, M, Walker, A, Klein, N

Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial by Post, F, Szubert, A, Prendergast, A, Johnston, V, Lyall, H, Fitzgerald, F, Musiime, V, Musoro, G, Chepkrorir, P, Agutu, C, Mallewa, J, Rajapakse, C, Wilkes, H, Hakim, J, Mugyenyi, P, Walker, A, Gibb, D, Pett, S, on behalf of the REALITY trial team

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa by Hakim, J, Musiime, V, Szubert, A, Mallewa, J, Siika, A, Agutu, C, Walker, S, Pett, S, Bwakura-Dangarembizi, M, Lugemwa, A, Kaunda, S, Karoney, M, Musoro, G, Kabahenda, S, Nathoo, K, Maitland, K, Griffiths, A, Thomason, M, Kityo, C, Mugyenyi, P, Prendergast, A, Walker, A, Gibb, D

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial by Kityo, C, Szubert, A, Siika, A, Heydermann, R, Bwakura-Dangarembizi, M, Lugemwa, A, Mwaringa, S, Griffiths, A, Nkanya, I, Kabahenda, S, Wachira, S, Musoro, G, Rajapakse, C, Etyang, T, Abach, J, Spyer, M, Wavamunno, P, Nyondo-Mipanda, L, Chidziva, E, Nathoo, K, Klein, N, Hakim, J, Gibb, D, Walker, A, Pett, S

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label,... by Mallewa, J, Szubert, A, Mugyenyi, P, Chidziva, E, Thomason, M, Chepkorir, P, Abongomera, G, Baleeta, K, Etyang, A, Warambwa, C, Melly, B, Mudzingwa, S, Kelly, C, Agutu, C, Wilkes, H, Nkomani, S, Musiime, V, Lugemwa, A, Pett, S, Bwakura-Dangarembizi, M, Prendergast, A, Gibb, D, Walker, A, Berkley, J, REALITY trial team

Clinical sub-phenotypes of Staphylococcus aureus bacteraemia by Swets, MC, Bakk, Z, Westgeest, AC, Berry, K, Cooper, G, Sim, W, Lee, RS, Gan, TY, Donlon, W, Besu, A, Heppenstall, E, Tysall, L, Dewar, S, de Boer, M, Fowler, VG, Dockrell, DH, Thwaites, GE, Pujol, M, Pallarès, N, Tebé, C, Carratalà, J, Szubert, A, Groeneveld, GH, Russell, CD